

# Treatment with doxycycline to promote the healing of chronic venous ulcer and markers of chronic venous insufficiency

<b>Submission date</b> 30/09/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 30/09/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 02/02/2017	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Prof Kevin Burnand

### Contact details

Guy's and St Thomas' NHS Foundation Trust  
General, Vascular and Colorectal Surgery Department  
F01 North Wing  
St Thomas' Hospital  
Lambeth Palace Road  
London  
United Kingdom  
SE1 7EH  
+44 (0)20 7188 2570  
Kevin.burnand@kcl.ac.uk

## Additional identifiers

### Protocol serial number

N0013146069

## Study information

**Scientific Title**

Treatment with doxycycline to promote the healing of chronic venous ulcer and markers of chronic venous insufficiency: a randomised controlled trial

**Study objectives**

1. Is haemosiderin a reliable marker for venous insufficiency?
2. Does the inhibition of matrix metalloproteinase play any role in the healing of ulcer?

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Cardiovascular: Venous ulcers

**Interventions**

Patients will be randomised into either treatment or control group. Each group will be matched according to ulcer size. The treatment group will take two daily 100mg of doxycycline and the patients in the control group will take matched placebo tablets. A biopsy from the ulcer will be obtained before the start of the study and at 8 weeks. Sample will be used to determine the Matrix Metalloproteinase (MMPs) level.

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Haemosiderin

**Primary outcome(s)**

Ulcer sizes, complete or incomplete healing

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

01/12/2007

# Eligibility

## Key inclusion criteria

Not provided at time of registration

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Not Specified

## Sex

Not Specified

## Key exclusion criteria

Not provided at time of registration

## Date of first enrolment

01/09/2003

## Date of final enrolment

01/12/2007

# Locations

## Countries of recruitment

United Kingdom

England

## Study participating centre

Guy's and St Thomas' NHS Foundation Trust

London

United Kingdom

SE1 7EH

# Sponsor information

## Organisation

Department of Health

# Funder(s)

## Funder type

Government

## Funder Name

Guy's and St. Thomas' NHS Foundation Trust (UK)

## Funder Name

Own Account - NHS R&D Support Funding

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes